Contents:

CONTACT DETAILS EXECUTIVE SUMMARY Scope Datamonitor insight into the cancer market The traditional treatment classes of cytotoxics, hormonals and adjuncts should continue to achieve strong sales in the short-term with the launch of novel efficacious agents, which complement the activity of innovative therapeutics The cancer market will see continued strong growth of the immunotherapies class and development of other innovative drug classes. Pharmaceutical companies should invest in the development or in-licensing of innovative cancer treatments to maintain market share Over the next decade, the rising incidence of most tumor types, and the higher cost of novel treatments, should ensure that the value of the cancer market continues to show strong growth year-on-year. This will ensure return on research investment for pharmaceutical developers Beyond 2010, the introduction of next-generation innovative therapies should enable further extension of survival and quality of life, eventually reducing cancer from a life-threatening illness to a well managed chronic illness. Market preference will shift towards those treatments that demonstrate the most favorable toxicity profiles in addition to excellent efficacy Summary analysis Key metrics CANCER MARKET REVIEW Background to the cancer market Cancer market segmentation by drug class Defining the cancer market Cytotoxic therapies Hormonal therapies Innovative therapies Adjunct therapies Market share by class Cancer market segmentation by company Research and development (R&D) investment Company pipelines Adjuncts review Hematopoietic growth factors (HGFs) Anti-emetics Bisphosphonates Analgesics Cytotoxics review Alkylating agents Anti-metabolites Cytotoxic antibiotics Vinka alkaloids and etoposide Other cytotoxics Hormonals review LHRH agonists Anti-estrogens Anti-androgens Progestagens Aromatase inhibitors Innovatives review Immunotherapies Growth inhibitors Gene therapies Antisense Other innovatives DISEASE REVIEW Introduction Breast cancer Disease description Epidemiology Current treatments Unmet needs Prostate cancer Disease description Epidemiology Current treatments Unmet needs Lung cancer Disease description Epidemiology Current treatments Unmet needs Colorectal cancer Disease description Epidemiology Current treatments Unmet needs Leukemia Disease description Epidemiology Current treatments Unmet needs Ovarian cancer Disease description Epidemiology Current treatments Unmet needs Brain cancer Disease description Epidemiology Current treatments Unmet needs Pancreatic cancer Disease description Epidemiology Current treatments Unmet needs Head and neck cancer Disease description Epidemiology Current treatments Unmet needs Malignant melanoma Disease description Epidemiology Current treatments Unmet needs PIPELINE ANALYSIS Introduction Classification of compounds Summary of cancer pipeline Breast cancer Early-stage compounds Late-stage compounds Prostate cancer Early-stage compounds Late-stage compounds Lung cancer Early-stage compounds Late-stage compounds Colorectal cancer Early-stage compounds Late-stage compounds Leukemia Early-stage compounds Late-stage compounds Ovarian cancer Early-stage compounds Late-stage compounds Brain cancer Early-stage compounds Late-stage compounds Pancreatic cancer Early-stage compounds Late-stage compounds Head and neck cancer Early-stage compounds Late-stage compounds Malignant melanoma Early-stage compounds Late-stage compounds COMPANY ANALYSIS Introduction Cancer market leaders Bristol-Myers Squibb Johnson & Johnson AstraZeneca Aventis Novartis Amgen GlaxoSmithKline Pharmacia Roche Schering-Plough Eli Lilly Emerging biotechnology companies Genentech ImClone OSI Pharmaceuticals ISIS Pharmaceuticals Genta Cancer pipeline summary Pipeline analysis by phase Pipeline analysis by indication Pipeline analysis by drug class FUTURE FOCUS Forecasting methodology Predicting first year market share Drug class growth Individual drug growth Influencing factors Influencing factors Increased prevalence Launch of new drug classes Expansion of existing drug classes Increased use of combination therapies Increased diagnosis Patent expiry and genericization Cost containment MediCare reformation Disease management Expansion of the cancer market Forecast incidence Forecast prevalence Market growth Forecast for novel agents in breast cancer treatment Breast cancer market overview Datamonitor opinion: Evista Datamonitor opinion: Gemzar Datamonitor opinion: Alimta Datamonitor opinion: Faslodex Datamonitor opinion: Genasense Datamonitor opinion: Tesmilifene Forecast for novel agents in prostate cancer treatment Prostate cancer market overview Datamonitor opinion: Eligard Datamonitor opinion: Atrasentan Datamonitor opinion: Plenaxis Datamonitor opinion: Provenge Forecast for novel agents in lung cancer treatment Lung cancer market overview Datamonitor opinion: Iressa Datamonitor opinion: ISIS 3521 Datamonitor opinion: BMS-184476 Datamonitor opinion: Navelbine Forecast for novel agents in colorectal cancer treatment Colorectal cancer market overview Datamonitor opinion: Orathecin Datamonitor opinion: Avastin Datamonitor opinion: Avicine Forecast for novel agents in niche cancers treatment Niche cancers market overview Datamonitor opinion: Gemzar Datamonitor opinion: IntraDose Datamonitor opinion: PEG-Intron A Datamonitor opinion: Advexin Datamonitor opinion: Allovectin-7 Datamonitor opinion: Erbitux Datamonitor opinion: Genasense Datamonitor opinion: Orathecin APPENDIX Glossary of terms Websites Cancer information Drug information Pharmaceutical companies Biotechnology companies References Master table of pipeline compounds